Drug Trial Radar · NCT05870670
A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men
Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
May 15, 2023
Primary completion
Oct 7, 2023
Study completion Oct 16, 2023
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes. This study, will look into how safe the new medicine NNC0519-0130 is, and we will measure its concentrations in the blood and look at its effects. This study will last for a maximum of 22 weeks and Japanese and Non-Japanese male participants will be included.
Conditions
- Diabetes Mellitus, Type 2
Interventions
NNC0519-0130Drug
Administered subcutaneously.
PlaceboDrug
Administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment PeriodTime frame: From pre-dose until 24 hours post-dose relative to last dose in each treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SOUSEIKAI Sumida Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.